Shares of Agenus Inc. (NASDAQ:AGEN) saw strong trading volume on Friday . 819,360 shares traded hands during trading, a decline of 24% from the previous session’s volume of 1,080,200 shares.The stock last traded at $4.11 and had previously closed at $4.04.

Several analysts have weighed in on the stock. BidaskClub raised shares of Agenus from a “hold” rating to a “buy” rating in a research note on Monday, July 24th. ValuEngine raised shares of Agenus from a “strong sell” rating to a “sell” rating in a research note on Monday, July 24th. Jefferies Group LLC reaffirmed a “buy” rating and set a $7.00 price objective on shares of Agenus in a research note on Friday, August 4th. Finally, Zacks Investment Research raised shares of Agenus from a “sell” rating to a “buy” rating and set a $4.50 price objective on the stock in a research note on Wednesday, July 5th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $5.88.

The company’s market cap is $414.80 million. The stock has a 50-day moving average price of $4.02 and a 200 day moving average price of $3.85.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.32) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.04. Agenus had a negative return on equity of 37,577.49% and a negative net margin of 280.96%. The firm had revenue of $4.21 million for the quarter, compared to the consensus estimate of $6.66 million. During the same quarter last year, the business posted ($0.33) earnings per share. The firm’s revenue was down 36.1% compared to the same quarter last year. Equities research analysts anticipate that Agenus Inc. will post ($1.13) EPS for the current fiscal year.

Institutional investors have recently made changes to their positions in the stock. TIAA CREF Investment Management LLC raised its position in Agenus by 0.6% in the second quarter. TIAA CREF Investment Management LLC now owns 204,576 shares of the biotechnology company’s stock valued at $800,000 after purchasing an additional 1,283 shares during the period. American International Group Inc. raised its position in Agenus by 7.1% in the first quarter. American International Group Inc. now owns 45,013 shares of the biotechnology company’s stock valued at $170,000 after purchasing an additional 2,984 shares during the period. The Manufacturers Life Insurance Company raised its position in Agenus by 6.7% in the second quarter. The Manufacturers Life Insurance Company now owns 63,595 shares of the biotechnology company’s stock valued at $248,000 after purchasing an additional 4,006 shares during the period. Metropolitan Life Insurance Co. NY raised its position in Agenus by 12.2% in the first quarter. Metropolitan Life Insurance Co. NY now owns 55,920 shares of the biotechnology company’s stock valued at $211,000 after purchasing an additional 6,101 shares during the period. Finally, Voya Investment Management LLC raised its position in Agenus by 18.5% in the second quarter. Voya Investment Management LLC now owns 40,855 shares of the biotechnology company’s stock valued at $160,000 after purchasing an additional 6,381 shares during the period. Hedge funds and other institutional investors own 39.51% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Agenus Inc. (AGEN) Sees Large Volume Increase” was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/09/08/agenus-inc-agen-sees-large-volume-increase-3.html.

Agenus Company Profile

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.